7 hours ago · Details about its next-generation weight loss drugs CagriSema and amycretin are also in focus. It's been a rocky few months for Novo Nordisk . 24/7 New York news stream: Watch NBC 4 free wherever ...

Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...

Jan 28, 2025 · Novo Nordisk has reported weight loss effects of up to 22% in patients who received a weekly subcutaneous dose of its next-generation weight loss drug, amycretin, over the course of 36 weeks. These topline results show early potential for the drug candidate to surpass the efficacy of Eli Lilly’s Zepbound (tirzepatide), one of its major ...

3 days ago · Novo Nordisk plans further clinical development of amycretin for obesity and overweight treatment. ... Investigators reported that treatment with amycretin showed an estimated weight loss of 9.7% on 1.25 mg of the subcutaneous injection (20 weeks), 16.2% on 5 mg (28 weeks) and 22% on 20 mg (36 weeks).

Sep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.

Jan 27, 2025 · Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight individuals. ... Subjects receiving the therapy experienced notable weight loss, with an estimated reduction of 9.7% on 1.25mg over 20 weeks, 16.2% on 5mg over 28 weeks, and 22% on 20mg over a 36-week period.

Sep 23, 2024 · An experimental new pill from Novo Nordisk, called amycretin, could cause substantial weight loss in people with obesity. The once-daily oral medication is in the same class as the blockbuster obesity and diabetes medications, Ozempic and Mounjaro.

Jan 17, 2025 · Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's...

Sep 10, 2024 · A daily weight loss pill from Novo Nordisk was shown to lower body weight by up to 13% after three months in a Phase 1 clinical trial, according to findings presented Tuesday at the European...

Jun 4, 2021 · Semaglutide 2.4 mg is a GLP-1 receptor agonist, with 94% similarity to naturally occurring human GLP-1 hormone. It induces weight loss by reducing hunger, increasing feeling of fullness and thereby helping people eat less and reduce their calorie intake.